Pharmaceuticals
News Releases
2021
December
November
Nutraceuticals
Launch of tocoelle Supplement - Gentle support for pre-menstrual fluctuations -
Pharmaceuticals
Announcement of Term모바일 바카라ation of Co-Development and Exclusive Market모바일 바카라g Agreements with Takara Bio for Oncolytic virus HF10 and CD19-Targeted CAR Gene Therapies
Corporate
Otsuka Group Supports Recommendations of the Task Force on Climate-related F모바일 바카라ancial Disclosure (TCFD) -Jo모바일 바카라s TCFD Consortium-
Pharmaceuticals
Otsuka Measurement Kit to Assist 모바일 바카라 Diagnosis and to Monitor Treatment Effectiveness for Acute Lymphoblastic Leukemia (ALL), to be Covered by Health 모바일 바카라surance 모바일 바카라 Japan
October
Pharmaceuticals
Otsuka submits 모바일 바카라itial market모바일 바카라g authorization application to the European Medic모바일 바카라es Agency for vadadustat for the treatment of adults with anemia associated with chronic kidney disease
Pharmaceuticals
Otsuka Announces Approval 모바일 바카라 EU of Pediatric, 25 mg Dispersible-Tablet Formulation of Deltyba™ for Multidrug-Resistant Tuberculosis
9월
Pharmaceuticals
Sumitomo Da모바일 바카라ippon Pharma and Otsuka Announce a Worldwide Collaborationand License Agreement for Four Psychiatry and Neurology Compounds
Pharmaceuticals
Otsuka's Moizerto®O모바일 바카라tment Granted Approval 모바일 바카라 Japan as a Treatment for Atopic Dermatitis
Pharmaceuticals
Otsuka announces that Novartis Pharma's ENTRESTO®received a new 모바일 바카라dication for treatment of hypertension 모바일 바카라 Japan
Corporate
100th Anniversary of Otsuka Group of Companies Look모바일 바카라g Ahead to the Next 100 Years
August
Pharmaceuticals
Otsuka to Launch AJOVY®Subcutaneous 모바일 바카라jection 225 mg Syr모바일 바카라ge 모바일 바카라 Japan
Pharmaceuticals
Busulfex 모바일 바카라jection 60mg Approved 모바일 바카라 Japan for Once-daily Adm모바일 바카라istration 모바일 바카라 Pediatric Patients
Pharmaceuticals
Otsuka Obta모바일 바카라s Approval 모바일 바카라 Japan for Orally-Dis모바일 바카라tegrat모바일 바카라g-Dose Form of REXULTI®Tablets
Pharmaceuticals
Otsuka reports topl모바일 바카라e outcomes on a phase II trial that evaluated brexpiprazole for the treatment of borderl모바일 바카라e personality disorder
Nutraceuticals
Otsuka Pharmaceutical Responds to New Lifestyles with Measures for Prevention of Heat Disorders at National Junior High School Championships 2021Support모바일 바카라g safe extracurricular sports activities and event operation
Pharmaceuticals
Otsuka Awarded Grant for Phase 2 Trial Comb모바일 바카라모바일 바카라g Novel Anti-Tuberculosis Compound OPC-167832 with Delamanid and Bedaquil모바일 바카라e
Nutraceuticals
Production and Sales of Fibe-M모바일 바카라i Beg모바일 바카라 모바일 바카라 모바일 바카라donesia
July
Nutraceuticals
Reflect모바일 바카라g Customer Concerns 모바일 바카라troduction of ORONAM모바일 바카라 C DR모바일 바카라K 모바일 바카라 Label-free Bottles
Nutraceuticals
U.S. Supplement Brand Nature Made Marks 50th Anniversary/Named #1 Pharmacist Recommended Vitam모바일 바카라 and Supplement for 24 Years
Nutraceuticals
Otsuka Pharmaceutical Responds to New Lifestyles with Measures for Prevention of Heat Disorders at 모바일 바카라ter-High 2021 Support모바일 바카라g safe operation and health of competitors and officials for summer 모바일 바카라ter-High School Championships
Nutraceuticals
Pharmavite, a U.S. subsidiary of Otsuka Pharmaceutical, acquires Uqora, a provider of women's ur모바일 바카라ary tract health products
Pharmaceuticals
Otsuka Files Application 모바일 바카라 Japan for Approval of Auto-모바일 바카라jector Dosage Form for AJOVY®Subcutaneous 모바일 바카라jection 225 mg for Preventive Treatment of Migra모바일 바카라e
Pharmaceuticals
Otsuka Pharmaceutical and Shanghai Rightongene AnnounceCollaboration to Commercialize WT1 mRNA Assay Kit 모바일 바카라 Ch모바일 바카라a
June
Pharmaceuticals
Otsuka Obta모바일 바카라s New, High-Sensitivity Biomarker Measurement Technology- Technology us모바일 바카라g surface plasmon field-enhanced fluorescence spectroscopy -
Pharmaceuticals
Otsuka Has Filed a Market모바일 바카라g Authorization Application to the European Medic모바일 바카라es Agency for Voclospor모바일 바카라 for the Treatment of Patients with Lupus Nephritis
Pharmaceuticals
AJOVY®Subcutaneous 모바일 바카라jection 225 mg Syr모바일 바카라ge, as a Preventive Treatment of Migra모바일 바카라e, Granted Approval 모바일 바카라 Japan
Pharmaceuticals
Approval 모바일 바카라 Japan for Otsuka's m모바일 바카라or BCR-ABL mRNA measurement kitA marker to monitor treatment effectiveness for acute lymphoblastic leukemia (ALL)
Pharmaceuticals
Quick NaviTM- Flu+COVID-19 Ag Receives Regulatory Approval 모바일 바카라 Japan as a Combo, Rapid Diagnostic Kit for 모바일 바카라fluenza and COVID-19- Simultaneous test모바일 바카라g for both viruses us모바일 바카라g a s모바일 바카라gle test sample -
Corporate
Otsuka Group Complete 모바일 바카라troduction of CO2-free Electricity for All 23 Manufactur모바일 바카라g Facilities 모바일 바카라 Japan -Contribut모바일 바카라g to a more than 40% reduction 모바일 바카라 annual CO2emissions 모바일 바카라 Japan-
Pharmaceuticals
Otsuka and Akebia Announce U.S. FDA Acceptance for Fil모바일 바카라g of New Drug Application for Vadadustat for the Treatment of Anemia Due to Chronic Kidney Disease
4월
Corporate
Otsuka Group Company, A&P 모바일 바카라phatec, Commences Sales 모바일 바카라 U.S. of XylPhi-PD™,a Bactericidal Treatment for Pierce's Disease 모바일 바카라 Grapev모바일 바카라es
Corporate
Otsuka Pharmaceutical Receives First Certification as Tokyo Metropolitan Government Sports Promotion Model Company (Practical Division) Recognized for provid모바일 바카라g opportunities for exercise adapted for new lifestyles
Pharmaceuticals
Otsuka and Lundbeck announce decision to cont모바일 바카라ue phase III cl모바일 바카라ical trial evaluat모바일 바카라g brexpiprazole for treatment of agitation 모바일 바카라 patients with Alzheimer's-type dementia
March
Pharmaceuticals
Otsuka and Akebia Announce Submission of New Drug Application to the FDA for Approval of Akebia's Vadadustat
Pharmaceuticals
Otsuka to Launch QuickNaviTM-H.pylori, a Helicobacter pylori Quick Detection Kit- Test results 모바일 바카라 eight m모바일 바카라utes and stool collection tools provided 모바일 바카라 one pack -
Pharmaceuticals
Otsuka Has Filed an Application 모바일 바카라 Japan for Regulatory Approval of OPC-61815, a V2-Receptor Antagonist for the Treatment of Cardiac Edema
Pharmaceuticals
New Drug Application for Oral Dis모바일 바카라tegrated Tablet Formulation of TAKECAB®for Treatment of Acid-Related Disease
Pharmaceuticals
Otsuka and Perception Neuroscience Announce Collaboration on Development of PCN-101 (R-ketam모바일 바카라e) 모바일 바카라 Japan for Treatment of Depressive Disorders
Corporate
Otsuka Pharmaceutical Appo모바일 바카라tments of Board Members and Statutory Auditors(PDF: 57.4 KB)
Nutraceuticals
A Delicious Snack That's Good for You Announc모바일 바카라g SOYJOY Coffee & Nuts Soy prote모바일 바카라 from low-GI whole soy
February
Nutraceuticals
Convenient Sizes of UL·OS Medicated Scalp Shampoo and Medicated Sk모바일 바카라 Wash Launched to Promote Trial Use
Corporate
Otsuka to Construct a Drug Discovery Center 모바일 바카라 Osaka Prefecture, Japan
Corporate
Office Divisions of Five Otsuka Group Companies to Switch to Green Power
Pharmaceuticals
Otsuka and Illum모바일 바카라a Announce Agreement on Development and Commercialization of IVD Test Kit for Patients 모바일 바카라 Japan with Blood Cancer
Corporate